Wang Dahai, Wang Fang, Ding Jie, Xiao Huijie, Zhong Xuhui, Liu Xiaoyu
Department of Pediatrics, Peking University First Hospital, Beijing 100034, China.
Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; Email:
Zhonghua Er Ke Za Zhi. 2015 Sep;53(9):670-5.
IgA nephropathy is the most common type of glomerulonephritis in the world. Its clinical and pathological manifestations vary. A few of the patients with IgA nephropathy present with rapidly progressive glomerulonephritis (RPGN) and/or crescent formation. Their conditions are serious and acute, but there are few reports on their characteristics, treatment and outcome. This study aimed to analyze the clinicalopathological features, treatment and prognosis of primary IgA nephropathy in children, to provide a reference for clinical diagnosis and treatment.
A retrospective study was conducted in children with primary IgA nephropathy with crescent formation and/or rapidly progressive glomerulonephritis admitted to our department from 2000 to 2014. The patients meeting the inclusion and exclusion criteria were included. Patients were divided into RPGN group and non-RPGN group according to the clinical manifestations, crescent formation group and non-crescent group, crescentic IgA nephropathy group and non-crescentic IgA nephropathy group according to renal biopsy. Their clinical manifestations and pathological features, treatment and prognosis were compared.
A total of 265 patients were recruited, 10 patients (3.8%) had RPGN, 151 patients (57.0%) had crescent formation, 19 cases (7.2%) showed crescentic IgA nephropathy.Compared with non-RPGN group, RPGN group showed more gross hematuria, higher serum creatinine, lower creatinine clearance correction at biopsy and follow-up, and more crescentic IgA nephropathy (P<0.05). The percent of patients who received methylprednisolone pulse and blood purification therapy in RPGN group is higher than that of non-RPGN group (P<0.05). Compared with non-crescent group, crescent formation group showed more gross hematuria at biopsy and follow-up, higher serum creatinine at biopsy, lower creatinine clearance correction, more 24-hour urinary protein at biopsy and higher serum creatinine at follow-up (P<0.05). The percentage of patients received more methylprednisolone pulse, oral steroids, cyclophosphamide pulse in crescent formation group was higher than that of non-crescent group (P<0.05). Compared with non-crescentic IgA nephropathy group, crescentic IgA nephropathy group showed more RPGN percent, higher serum creatinine, more 24-hour urinary protein at biopsy (P<0.05). The percentage of patients who received more methylprednisolone pulse and blood purification therapy in crescentic IgA nephropathy group was more than non-crescentic IgA nephropathy group (P<0.05). At follow-up, 20.0% of the patients with RPGN and crescent nephritis returned to normal renal function and the percent of crescent glomerulonephritis but not RPGN was 71.4%, RPGN but not crescent glomerulonephritis was 80.0%, crescent formation but not crescent nephritis was 87.5%.
In primary IgA nephropathy with crescent formation and/or rapidly progressive glomerulonephritis, the patients with both RPGN and crescentic IgA nephropathy showed the worst clinical manifestations, its prognosis was worst while the patients with crescent formation showed the mildest clinical manifestations and best prognosis.
IgA肾病是全球最常见的肾小球肾炎类型。其临床和病理表现各异。少数IgA肾病患者表现为快速进展性肾小球肾炎(RPGN)和/或新月体形成。他们的病情严重且急性,但关于其特征、治疗和预后的报道较少。本研究旨在分析儿童原发性IgA肾病的临床病理特征、治疗及预后,为临床诊断和治疗提供参考。
对2000年至2014年入住我科的原发性IgA肾病合并新月体形成和/或快速进展性肾小球肾炎的儿童进行回顾性研究。纳入符合纳入和排除标准的患者。根据临床表现将患者分为RPGN组和非RPGN组,根据肾活检分为新月体形成组和非新月体组、新月体性IgA肾病组和非新月体性IgA肾病组。比较他们的临床表现、病理特征、治疗及预后。
共纳入265例患者,10例(3.8%)为RPGN,151例(57.0%)有新月体形成,19例(7.2%)为新月体性IgA肾病。与非RPGN组相比,RPGN组肉眼血尿更多、血清肌酐更高、活检及随访时校正的肌酐清除率更低,新月体性IgA肾病更多(P<0.05)。RPGN组接受甲泼尼龙冲击和血液净化治疗的患者百分比高于非RPGN组(P<0.05)。与非新月体组相比,新月体形成组活检及随访时肉眼血尿更多、活检时血清肌酐更高、校正的肌酐清除率更低、活检时24小时尿蛋白更多、随访时血清肌酐更高(P<0.05)。新月体形成组接受更多甲泼尼龙冲击、口服糖皮质激素、环磷酰胺冲击治疗的患者百分比高于非新月体组(P<0.05)。与非新月体性IgA肾病组相比,新月体性IgA肾病组RPGN百分比更高、血清肌酐更高、活检时24小时尿蛋白更多(P<0.05)。新月体性IgA肾病组接受更多甲泼尼龙冲击和血液净化治疗的患者百分比高于非新月体性IgA肾病组(P<0.05)。随访时,RPGN和新月体肾炎患者中20.0%肾功能恢复正常,新月体性肾小球肾炎但非RPGN患者为71.4%,RPGN但非新月体性肾小球肾炎患者为80.0%,新月体形成但非新月体肾炎患者为87.5%。
在原发性IgA肾病合并新月体形成和/或快速进展性肾小球肾炎中,同时患有RPGN和新月体性IgA肾病的患者临床表现最差,预后最差,而有新月体形成的患者临床表现最轻,预后最好。